| Autor: |
Zhang Z; Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China., Wang Q; Department of Immunization and Prevention, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China., Zhu Q; Department of Immunization and Prevention, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China., Bai S; Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China., Liu Y; Department of Immunization and Prevention, Chongqing Municipal Center for Disease Control and Prevention, Chongqing, China., Ren J; Department of Immunization and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China., Xu X; Department of Immunization and Prevention, Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China., Qu J; Department of Immunization and Prevention, Tianjin Center for Disease Control and Prevention, Tianjin, China., Pan J; Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China., Lu L; Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China., Suo L; Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China., Sun X; Department of Immunization and Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China., Zhang Y; Department of Immunization and Prevention, Tianjin Center for Disease Control and Prevention, Tianjin, China., Wu J; Department of Immunization and Prevention, Beijing Center for Disease Prevention and Control, Beijing, China. |
| Abstrakt: |
This study aimed to evaluate the seroprevalence of Bordetella pertussis and persistence of antibodies following vaccination. We recruited 6060 healthy subjects from five provinces of China during 2017-2018. Serum IgG antibodies against pertussis toxin (anti-PT IgG) and filamentous hemagglutinin (anti-FHA IgG), and serum IgA antibodies against pertussis toxin (anti-PT IgA) were measured by ELISA. Geometric mean concentration (GMC), seropositivity rate, and recent infection rate were calculated. Among 0-6 years-olds, the anti-PT IgG, anti-PT IgA, and anti-FHA IgG GMCs were 6.4 IU/ml (95% CI 6.1-6.8), 2.8 IU/ml (95% CI 2.7-2.8), and 13.3 IU/ml (95% CI 12.4-14.2), respectively. The anti-PT IgG GMC increased in accordance with the primary vaccination series (4-6 months) and the toddler booster (18-24 months), but declined thereafter through to age 5 years [4.7 IU/ml (95% CI 4.2-5.4)]. The seropositivity rate of pertussis in >6 year-olds was 9.0% (95% CI 8.1-9.9) and the recent infection rate was 3.3% (95% CI, 2.7-3.8). Recent infection rate began to increase from 6 years of age, with peaks at 9, 20, 40, and ≥60 years of age. The anti-PT IgG GMCs of children aged 0-6 years who were vaccinated with DTaP, DTaP-IPV//PRP～T, and DTaP-Hib were 5.9 IU/ml (95% CI 5.6-6.3), 20.7 IU/ml (95% CI 15.6-27.8), and 11.7 IU/ml (95% CI 7.5-18.1) ( p < .001), respectively ( p < .001). Pertussis vaccination improves anti-PT IgG levels, however these wane soon after vaccination. Sero-estimated recent infection rates appear to increase from school age into adolescence and adulthood. Pertussis vaccine boosters should be considered in these age groups. |
